AUTHOR INDEX

Bagchi, I. 255
Bar-Sinai, A. 271
Breton, P. 285

Cantin, E. M. 245
Casteels, R. 191
Chang, P. A. 245
Cho-Chung, Y. S. 1
Clair, T. 1
Czuba, M. 147

Davies, P. 321
Declerck, I. 191
De Smedt, H. 191
Droogmans, G. 191

Garbers, D. L. 337
Gause, B. L. 285
Grzegorzewski, K. 285

Hastings, M. H. 35
Hayes, J. D. 443

Jackson, T. 425
Judah, D. J. 443

Klotz, U. 223
Kroemer, H. K. 233

Levitzki, A. 271
Little, H. J. 347
Lu, K. P. 255

McLellan, L. I. 443
Means, A. R. 255
Missiaen, L. 191
Morley, S. J. 291

Neal, G. E. 443
Newton, S. A. 285

Olden, K. 285
Oredipe, O. A. 285

Payne, D. 95

Raeymaekers, L. 191
Randall, M. D. 73
Rasmussen, C. D. 255
Rossi, J. J. 245

Sarver, N. 245
Scott, J. D. 123
Smith, I. C. P. 147

Thomas, G. 291
Tortora, G. 1

VanBerkum, M. F. A. 255

Weckbecker, G. 367
Wernsdorfer, W. H. 95
White, S. L. 285
Wuytack, F. 191

Yasuda, Y. 285
Yokozaki, H. 1

SUBJECT INDEX

N-Acetyltransferase
  circadian rhythm 45, 50
  photoperiodism 58
Acivicin, modulation of fluorouracil action 387
ACTH
  circadian rhythms 46
  circhoral pulsatility 37
Actin, effect of calmodulin on expression of 263
Adenosine, modulation of fluorouracil action 385
Adenosine-3′,5′-monophosphate
  cell proliferation 4
  dependent protein kinase 2
  hormone and growth factor interaction 15
  malignancy 12
  mechanism of action 20
  melatonin effects on 61
  ontogeny and differentiation 8
  reversal of malignancy 14
  signalling pathways 125
  therapeutic potential of site-selective analogs 23
Adenosine-3′,5′-monophosphate analogs 2
  binding to protein kinases 3
  differentiation of leukemia 11
  growth arrest of human cancer cell lines 7
  therapeutic potential 23
Adenosine-3′,5′-monophosphate-dependent protein kinase 2, 123
  abnormal isoenzyme patterns in malignancy 13
  binding affinity of cAMP analogs 3
  catalytic subunit 125, 126
  cell proliferation 4
  function 133, 136
  nuclear translocation 20
  ontogeny and differentiation 9
  regulation of endoplasmic reticulum Ca^{2+} pump 209
  regulation of plasma-membrane Ca^{2+} pump 198
  regulatory subunits 128
  reversal of malignancy 15
  role of 20
Adenosine-3′,5′-monophosphate response element binding protein 22, 134
Ca^{2+}-Adenosine triphosphatase, plasma membrane 192
Adenosine triphosphate
  dependent calcium sequestration, effect of ethanol 351
  regulation of plasma membrane Na^{+}–Ca^{2+} exchange 203
β-Adrenergic receptor
  adenylyl cyclase/G protein system 272
  G protein coupling 427, 430, 432
Adenylyl cyclase
  carcinogenesis 13
  functional units 271
  regulation by receptor-operated G proteins 271–283
  stimulation 273
Adhesion molecules, expression by lung 327
Aflatoxicosis 445
Aflatoxin B_1
  association with diseases in man 445
  experimental toxicology 446
  glutathione *S*-transferases in metabolism 450, 456, 462
  mechanisms of toxicity 447
  metabolites 445
  production and distribution 444
  resistance 454, 455, 463
  toxification and detoxification 448
  transport 453
Airways, morphology and morphometry 329
Alcohol dependence 348
AlF_4, inhibition of endoplasmic reticulum Ca^{2+} pump 213
Alkaline phosphatase, marker of malignancy 153
8–Aminoquinolines, malaria treatment 100
Annual endocrine rhythms 54
Antiarrhythmic drugs, ranitidine interaction 237
Anticoagulants, ranitidine interaction 236
Antidiabetics, ranitidine interaction 236
Antigen expression, lung, drug-induced 326
Antigenicity in tumors 149
Anti-inflammatory drugs, ranitidine interaction 238
Antioxidant Responsive Element, aflatoxin B_1 resistance 456, 466
Antisense inhibition 245
  anti-HIV-1 ribozymes 247
  therapeutic use 252
Antisense oligonucleotides 17, 307
Arachidonic acid, effect on plasma membrane Ca^{2+} pump 195
Arginine vasopressin 40
Aspergillus nidulans, calmodulin gene 264
Aspirin, effect of ranitidine on absorption 234
Atrial natriuretic peptide, effect of endothelin-1 on release 86
Atrial natriuretic peptide clearance receptor 340
Atrial natriuretic peptide receptor 339
Atriopeptin III, endothelin-1 interaction 87
Autocrine differentiation-inhibiting factor 181
Autonomic nervous system, endothelin interactions 87

Barbiturates, calcium channels and dependence 357
BAU, modulation of fluoropyrimidine action 387
Bay K 8644, ethanol interaction 355
Benzodiazepines, calcium channels and dependence 358
N^6-Benzyl-cAMP, effect on cell growth 11
Biological clocks 35
Blood group antigens, relation to antigens in neoplasma 160
Blood pressure, endothelins 78, 87
B-2 microglobulin, malignancy 154
Bone marrow, effect of swainsonine 287

Brain, endothelin-1 effects on circulation 81
Brain natriuretic peptide 340
Breast cancer
  cAMP in 12
  cAMP-dependent protein kinases 13
  fluoropyrimidine/thymidine effects 382
Bromovinyluracil 374

Calcitonin, tumor marker 156
Calcium
  endoplasmic reticulum transport 206
    Ca^{2+}/H^+ exchange-dependent Ca^{2+} uptake 214
    Ca^{2+} pump 206
    refilling of stores 214
  ethanol effects on cell content and uptake 349
  mitochondrial transport 216
  plasma membrane transport 192
    Ca^{2+} pump 192
    Na^+–Ca^{2+} exchange 201
Calcium antagonists
  benzodiazepine interaction 359
  ethanol interaction 355
  opiate interactions 360
  effect on vascular responses to endothelins 87
Calcium–calmodulin complex 255
  control of cell proliferation 262
Calcium channels
  role in barbiturate dependence 357
  role in benzodiazepine dependence 358
  role in ethanol dependence 353–357
  role in opiate dependence 359
Calcium/hydrogen exchange, dependent Ca^{2+} uptake 214
Calcium mobilizing agonists, regulation of plasma membrane Ca^{2+} pump 194
Calcium pump
  endoplasmic reticulum 206
  plasma membrane 192
Calmodulin 255
  control of cell proliferation 262
  expression plasmids 267
  molecular genetics 264
  regulation of dependent enzymes 258
  regulation of plasma-membrane Ca^{2+} pump 197
  structural requirements for binding 257
Cancer
  markers for 147–190
    biological 151
    efficiency 179
    ethical problems 180
    monoclonal and polyclonal antibodies 170
    NMR 171
  swainsonine treatment 285
Cancer cells, growth arrest by site-selective cAMP analogs 7
Carcinoembryonic antigen 151, 165, 168
Carcinogenesis, cAMP levels 13
Cardiovascular actions of endothelins 78
  endogenous modulation 84
  effect of hypoxia 86
  pathophysiology 87
  pharmacological modifications 87
  structure–activity relationships 81
Cardiovascular drugs, ranitidine interaction 237
Carr–Purcell pulse sequence, tumor detection 173
Casein kinase II 295
Catalytic RNAs 246
  anti-HIV-1 247
  cytotoxicity 252
  delivery to cells 249
  intracellular expression and gene therapy 251
Cefpodoxime, effect of ranitidine on bioavailability 234
Cell cycle re-entry, effect of calmodulin 264
Cell proliferation
  antigens 164
  calmodulin 262
  cAMP 4
  protein synthesis and mitogenic response 302
  swainsonine 287
Cerebral vasospasm, endothelins 81, 88
Chemoprotection 455
Chinese hamster ovary fibroblasts, cAMP-dependent protein kinases 6
Chloroquine, resistance in *Plasmodium falciparum* 96, 102, 114
Chromaffin cells, 140 kDa intracellular Ca^{2+} pump 214
Chromosomal changes in neoplasms 168
5,10-CH_2-tetrahydrofolate 394
Cimetidine, drug interactions 234–240
Circadian rhythms
  fluoropyrimidine pharmacology 401
  neuroendocrine secretion 45
    functional significance 52
    neural basis to entrainment of 50
    suprachiasmatic nuclei 47
Circannual clocks 55
Circhoral pulsatility
  hypothalamic control of secretion by anterior pituitary 39
  hypothalamic pulse generators 40
  hypothalamo-pituitary axis 36
  neuroendocrine control 37
  target tissues 43
Cisplatin, modulation of fluorouracil action 396
8-Cl-cAMP 2
  differentiation of leukemia 11
  effect on human cancer cell lines 7
  modulation of cAMP receptor protein 15
  therapeutic potential 23
  transforming growth factor-α interaction 16
c-*myc*, effect of cAMP analogs 16
Colon tumors, MRS in detection 172
Colony stimulating factors 288
  modulation of fluoropyrimidine action 398
Compound 48/80, inhibition of plasma-membrane Ca^{2+} pump 197
Congestive cardiac failure, endothelins 88
Corticosteroids, circadian rhythms 46, 52
Corticotropin releasing hormone 40
COSY spectroscopy, tumor detection 174
Creatine kinase, association with malignancy 154
C-type natriuretic peptide 340
Cyclic nucleotide-dependent protein kinase, cAMP 2, 123
  abnormal isoenzyme patterns in malignancy 13
  binding affinities of cAMP analogs 3
  catalytic subunit 126
  cell proliferation 4
  function 133, 136
  nuclear translocation 20
  ontogeny and differentiation 9
  regulation of plasma-membrane Ca^{2+} pump 198
  regulatory subunits 128
  reversal of malignancy 15
  role of 20

Cyclic nucleotide-dependent protein kinase, cGMP
  regulation of plasma-membrane Ca^{2+} pump 199
  structure 135
  substrate specificity and function 136
Cyclin A/B 307
Cyclooxygenase inhibition, effect on endothelin acitivity 85
Cyclopiazonic acid, inhibition of endoplasmic reticulum Ca^{2+} pump 214
Cyclosporin A, ranitidine interaction 237
Cysteine, modulation of fluoropyrimidine action 397
Cytochrome P450, aflatoxin B_1 metabolism 449

Deoxyinosine, modulation of fluorouracil action 386
Deoxynucleotide transferase, differentiation of leukemia 11
Deoxyuridine monophosphate 376
Diazepam, effect on calcium channels 358
5-Diazouracil 374, 381
2,5-Di(*tert*-butyl)-1,4-benzohydroquinone, inhibition of endoplasmic reticulum Ca^{2+} pump 213
$N^6O^{2'}$-Dibutyryl-cAMP, cell proliferation 4, 7, 9
Differentiation
  antigens 164
  cAMP 8, 11
Difucosyllacto-*N*-nor-hexaosylceramide 161
Dihydrofolate reductase inhibitors, malaria treatment 100
Dihydrouracil dehydrogenase, inhibitors 374
Dihydropyridines
  binding in brain 352
    effect of barbiturates 358
    effect of benzodiazepines 358
    effect of ethanol 354
    effect of opiates 359
  role in ethanol dependence 357
Dihydropyrimidinase 374
2,6-Dihydroxypyridine 388
Dipyridamole, modulation of fluoropyrimidine action 388
DNA
  aflatoxin B_1 binding 447, 453
  cAMP and synthesis of 9
Double-strand RNA activated enzyme 296
Doxifluridine 403
Drug resistance, *Plasmodium falciparum* 95–121

eIF-2 293
eIF-2 kinases 296
eIF-4, phosphorylation, mitogenic response 296, 303
eIF-5 299
Elongation factors, protein synthesis 300
Endoplasmic reticulum, Ca^{2+} transport 206
  Ca^{2+}/H^+ exchange-dependent Ca^{2+} uptake 214
  Ca^{2+} pump 206
  refilling of stores 214
Endothelins
  cardiovascular actions 78
    endogenous modulation 84
    effect of hypoxia 86
    pathophysiology 87
    pharmacological modifications 87
    structure–activity relationships 81
  identification 74
  mechanism of action 77
  pharmacokinetics 77
  receptors 76
  synthesis and release 75
Endothelium-derived contracting factor 75
Endothelium-derived relaxing factor 74
  hypoxia 86
  modulation of vascular responses to endothelins 84
Endotoxic shock, endothelins 89
Enoxacin, effect of ranitidine on bioavailability 234
Epidermal growth factor 305
  modulation of fluorouracil action 398
eRF 301
Estrogen
  cAMP interaction in mammary tumors 15
  markers for malignancy 155
Estrous cycle
  circadian basis 46, 53
  seasonality 55
Ethanol
  Calcium channels and dependence 357
  dependence, tolerance and withdrawal 348
  effect on neuronal calcium channels 349
Excitatory amino acids, effect on hypothalamic pulsatility 42
Expression plasmids, role of calmodulin 267

Ferritin, malignancy 154
α-Fetoprotein 151, 154
Flow cytometry, tumor markers 168
α-Fluoro-β-alanine 375
5-Fluorodeoxyuridine 5′-monophosphate
  detection 410
  formation 370
  inhibition of thymidylate synthase 375
5-Fluorodeoxyuridine 5′-triphosphate 380
Fluoropyrimidines 368
  chronopharmacology 401
  detection and analysis 405
  metabolism 369
  modulation of metabolism 381
  pharmacokinetics 399
  prodrugs 403
  resistance 401
  synthesis and chemical properties 405
  toxic metabolites 375
  transport 369
Fluorouracil
  chronopharmacology 401
  containing DNA 380, 383
  containing RNA 378, 383
  detection and analysis 406
  metabolism 370
  modulation of metabolism 381–399
  pharmacokinetics 399
  prodrugs 403
  resistance 401
  synthesis 405
  transport 369
Fluorouracil-glucuronide 373
Fluorouridine diphosphate-sugars 371, 373
  analysis 409
Fluorouridine triphosphate, effect on RNA synthesis 377
Folates, modulation of fluoropyrimidine action 390, 392
Follicle stimulating hormone, pulsatile secretion 43
Fossel test 176
Fucosylation, glycolipids, tumor markers 158, 175

α-Galactosamine, modulation of fluoropyrimidine action 389
Galactosyltransferase, marker of malignancy 153
Gastric acid secretion, ranitidine 234
Gene transcription, cAMP 22
Germinal vesicle breakdown 307
Glibenclamide, ranitidine interaction 236
Glucocorticoid receptors, circadian rhythms 52
Glucose 6-phosphate dehydrogenase, association with malignancy 154, 168
γ-Glutamyl transpeptidase, marker of malignancy 153
Glutathione *S*-transferase, aflatoxin B_1 metabolism and toxicity 447, 450, 456, 462
Glyburide, ranitidine interaction 236
Glycosphingolipids, tumor markers 156, 174
G proteins 425
  regulation of adenylyl cyclase 271–283
  regulation of plasma-membrane Ca^{2+} pump 200
G protein coupled receptors 426
  desensitization and downregulation 436
  efficacy 435
  specificity 433
  structures 427
  structure–function relationships 430
Growth factors, modulation of fluoropyrimidine action 398
Growth hormones
  cAMP interaction 15
  circadian rhythms 46
  circhoral pulsatility 37, 43
Growth hormone releasing hormone, circhoral pulsatility 39, 43
Guanosine, modulation of fluorouracil action 385
Guanosine-3′,5′-monophosphate
  role in endothelin-1 release 76
  signalling pathways 125
Guanosine-3′,5′-monophosphate-dependent protein kinase
  activation 133
  catalytic and regulatory units 125
  regulation of plasma membrane Ca^{2+} pump 199
  structure 135
  substrate specificity and function 136
Guanosine triphosphate, inhibition of endoplasmic reticulum Ca^{2+} pump 213
Guanylyl cyclase
  heterodimeric forms 338, 341
  mechanisms of regulation 341
  plasma membrane forms 338, 341
Guanylyl cyclase-linked receptors 337–345

Halofantrine 113, 116
Heart
  effect of endothelins 78, 81
  regulation on endoplasmic reticulum Ca^{2+} pump 208, 210
Heme-controlled repressor 296
Hemodynamics, endothelins 78
Hepatocyte nodules, aflatoxin B_1 463
Hepatomas, cAMP in 12
L-Histidinol, modulation of fluoropyrimidine action 396
HIV-1, catalytic RNAs in therapy 247
Hormones, association with malignancy 154
5-Hydroxytryptamine, endothelin-1 interaction 87
Hypertension, endothelins 87
Hypothalamo-pituitary axis, pulsatile secretion 36
Hypothalamus
  control of pulsatile secretion by anterior pituitary 39
  pulse generators, anatomical basis 40
Hypoxia, endothelin release 75, 86

Ibuprofen, effect of ranitidine on absorption 234
Immune effector cells, effect of swainsonine 287
Immunoglobulins, tumor markers 165
Indomethacin, ranitidine interaction 238
Inflammation, lung
  morphology and morphometry 329
  stereologic techniques 327
Initiation factors, protein synthesis 293, 303, 306
Inosine, modulation of fluorouracil action 386
Inositol phosphates, regulation of plasma-membrane Ca^{2+} pump 195, 201
In situ hybridization, lung 326
Insulin, protein synthesis 305
Interferons, modulation of fluoropyrimidine action 397

Kemptide 133
Kidney
  endothelins 88
  ranitidine and drug secretion 235
Killer cells 165, 167
Kwashiorkor, role of aflatoxins 445

Lacto-*N*-fucopentaosylo(III)ceramide 161
Leucovorin, modulation of fluorouracil action 393
Leukemia, differentiation by site-selective cAMP analogs 11
Levamisole, modulation of fluorouracil action 398
Lewis antigens 159, 160
Lidocaine, ranitidine interaction 237
Light/dark cycle, neuroendocrine secretion 45
Lipid-bound sialic acid, tumor marker 163
Lipoproteins, indicative of malignancy, ^1H MRS 175
Liposomes, ribozyme encapsulation 250
Liver, ranitidine and drug elimination 235
Liver cancer, aflatoxin induced 445
Lung, drug-induced toxicity 321–336
  airways 329
  morphologic analysis 324, 328
  morphology and morphometry of tissue compartments 328
  preparative methods 322
  respiratory parenchyma 328
  vasculature 331
Luteinizing hormone
  circadian rhythm 47
  circhoral pulsatility 37
  photoperiodism 59
Luteinizing hormone releasing hormone
  circadian rhythm 47
  circhoral pulsatility 38, 40, 41
Lymphoma cells S49, cAMP-dependent protein kinases 6

Macrophages, effect of swainsonine 287
Magnetic resonance imaging, detection and diagnosis of cancer 171
Magnetic resonance spectroscopy, detection and diagnosis of cancer 171
  colon and ovarian tumors 172

lipoprotein fractions indicative of malignancy 175
plasma and serum analysis 176
premalignant tissues 175
Malaria, drug resistance in *Plasmodium falciparum* 95–121
Malignancy-associated lipoprotein 175
Malignant cells
antigenicity 149
role of cAMP 11
Mammary tumors, estrogen–cAMP interaction 5, 15
Maturational agents, modulation of fluorouracil action 398
Maturation promoting factor 308
Mefloquine
malaria treatment 100
resistance in *Plasmodium falciparum* 113, 116
Meiotic maturation, protein synthesis 306
Melatonin
circadian rhythms 45, 50, 53
photoperiodism 57
sites and mechanisms of action 60
Melittin 257
Metastasis, effect of swainsonine 285
Methotrexate, modulation of fluorouracil action 390
Metoprolol, ranitidine interaction 237
N-Methyl-D-aspartate antagonists, barbiturate dependence 358
N-Methylformamide, modulation of fluorouracil action 398
Microtubule associated protein 2, interaction with cAMP-dependent protein kinase 129
Midazolam, ranitidine interaction 234
Mineralocorticoid receptors, circadian rhythms 52
Misonidazole, tumor marker 168
Mitochondria, Ca^{2+} transport 216
Mitogenesis, protein synthesis 302
Monoclonal/polyclonal antibodies, tumor markers 170
Monocrotaline, pneumotoxicity, morphology and morphometry 332
Morphine, calcium channels and dependence 360
Muscarinic receptors, G protein coupling 433
Myocardial infarction, endothelins 88
Myosin light chain kinase, calmodulin and regulation of 258

Natriuretic peptide receptors 339, 340
Natural killer cells, effect of swainsonine 287
Neuroblastoma, ^{31}P MRS 179
Neuroendocrine rhythms 35–71
annual 54
circadian 45
circhoral pulsatility 36
Neuropeptide Y, endothelin interaction 87
Nifedipine, opiate interaction 360
Nimodipine
ethanol interaction 355
opiate interaction 360
Nitrendipine
benzodiazepine interaction 359
ethanol interaction 355
ranitidine interaction 237
Nitrobenzylthioinosine, modulation of fluorouracil action 389
Nonsteroidal anti-inflammatory drugs, ranitidine interaction 238
Nuclear Magnetic Resonance, detection and diagnosis of cancer 171

Oncogenes, tumor markers 168
Ontogeny, role of cAMP 8
Oogenesis, protein synthesis 306
Opiates, calcium channels and dependence 359
Orotate phosphoribosyltransferase 370
Ovarian follicles, cAMP-dependent protein kinase 10
Ovarian tumors, MRS in detection 172

p^{39mos} 307
PALA, modulation of fluorouracil action 386
Papaverine, neuroblastoma treatment 5
Peptides, tumor markers 156
Phosphatidylinositol-specific phospholipase Cγ 305
Phosphodiesterase inhibitors, cancer therapy 5
Phosphodiesterases, in malignant cells 12
Phosphofructokinase, marker of malignancy 153
Phospholamban, regulation of endoplasmic reticulum Ca^{2+} pump 208
Phospholipids, regulation of plasma-membrane Ca^{2+} pump 195
5-Phosphoribosyl 1-pyrophosphate pools, modulation of fluorouracil effects 390
Photoperiodism
pineal gland 57
vs circannual clocks 55
Photosensitive hematoporphyrin derivatives, tumor localization 168
Pineal gland
circadian rhythm 50
photoperiodism 57
Pirenzepine, ranitidine interaction 238
Pituitary, pulsatile secretion 37
Plasma membrane Ca^{2+} pump 192
regulation 194
Plasma membrane Na^+–Ca^{2+} exchange 201
molecular properties 204
regulation 203
Plasmodium falciparum, drug resistance 95–121
Platelet-derived growth factor 305
Platelets
effect of endothelin-1 85
regulation of Ca^{2+} pump 211
PN 200–110, ethanol interaction 355
Polyamines
as markers of malignancy 153
effect on mitochondrial Ca^{2+} transport 217
regulation of plasma-membrane Ca^{2+} pump 197
Potassium, rhythm of excretion 52
Potassium conductance, calcium-mediated, effect of ethanol 353
Premalignant tissues, ^{1}H MRS 175
Primaquine, malaria treatment 100
Procainamide, effect of ranitidine on renal secretion 235
Progestins, malignancy 155
Prolactin, circadian rhythms 46
Prostanoids, modulation of vascular responses to endothelins 85
Protein kinases
for eIF-2α 296
protein synthesis during meiotic maturation 306
protein synthesis during mitogenic response 302
Protein kinase C, regulation of plasma-membrane Ca^{2+} pump 199
Protein kinases, cyclic nucleotide dependent 123–145
regulation of plasma-membrane Ca^{2+} pump 198

site-selective cAMP analogs in malignancy 1–31
Protein kinase inhibitor 131
Protein p21, effect of cAMP analogs 16
Protein S-100, malignancy 154
Protein synthesis 292
  elongation phase 293, 300
  initiation 293
  meiotic maturation 306
  mitogenic response 302
  signal transduction 302
  termination 301
Protooncogenes, effect of cAMP analogs 16
Pyrimethamine 98, 100
Pyrimidine nucleoside phosphorylase inhibitors, modulation of fluoropyrimidine action 387
Pyrimidine phosphoribosyltransferase, fluorouracil metabolism 370

Quinine
  resistance in *Plasmodium falciparum* 112, 115
  treatment of malaria 96, 100

Ranitidine, drug interaction potential 233
  drug absorption 234
  hepatic elimination 235
  pharmacological properties 234
  renal secretion 235
Raynaud's phenomenon, endothelins 88
Renin, effect of endothelin-1 on release 86
Respiratory parenchyma, morphology and morphometry 328
Reye's syndrome, role of aflatoxins 445
Rhodopsin 427, 430, 437
Rhythmicity, neuroendocrine 36
Ribozymes 246
  anti-HIV-1 247
  cytotoxicity 252
  delivery to cells 249
  intracellular expression and gene therapy 251
RNA
  5-fluorouracil containing 378
  effect of 5-fluorouridine 5′-triphosphate on synthesis 377
mRNA, protein synthesis 292, 299
mRNA binding proteins 307
mRNA transcripts, expression in lung 326
Ruthenium red
  inhibition of mitochondrial Ca^{2+} transport 217
  inhibition of plasma-membrane Ca^{2+} pump 197

Sarafotoxin S6b 74
  effect of prostanoids on vascular response 85
  vasoconstriction 79
Seasonal Affective Disorder 60
Seasonality of endocrine and metabolic function 54
Sedatives/hypnotics, role of calcium channels in dependence 347–365
SERCA gene family 192, 206
Sexual behavior
  circadian clock 53
  seasonality 55
Signal transduction
  G proteins 426
  G proteins-adenylyl cyclase 271
  protein synthesis 302
S6 kinase 298, 303, 305, 306
Sodium–calcium exchange, plasma membranes 201
  molecular properties 204
  regulation 203
Somatostatin 39, 43
Species differences, susceptibility to aflatoxin B_1 446
Spermidine/spermine, marker of malignancy 153
Ste2/α-mating factor receptors 437
Stereologic techniques, lung 324
Subarachnoid hemorrhage, endothelins 88
Sulfadoxine + pyrimethamine
  malaria treatment 98
  resistance in *Plasmodium falciparum* 111
Suprachiasmatic nuclei, as circadian clocks 47, 53
Swainsonine, anticancer and immunomodulatory properties 285–290
Synaptosomes, effect of ethanol on calcium content 352

TaM-BM1 257, 268
Tegafur 403
Thapsigargin, effect on endoplasmic reticulum Ca^{2+} pump 213
Theophylline, effects of ranitidine and cimetidine on clearance 236
Thymidine, modulation of fluoropyrimidine action 381
Thymidylate synthase
  determination 411
  fluoropyrimidine resistance 401
  inhibition by FdUMP 375
Tolbutamide 236
Transforming growth factor α, cAMP interaction 16
Triazolam, effect on locomotor rhythms 51
Troponin 257
Tubulin, effect of calmodulin on expression of 263
Tumor-associated antigens 156
Tumor markers 149
Tumor metastasis and growth, effect of swainsonine 285

β-Ureidopropionase 374
Uridine, modulation of fluoropyrimidine action 384
Uridine diphosphate-sugars, modulation of fluoropyrimidine action 389
Uridine kinase, fluorouracil metabolism 371
Uridine phosphorylase, fluorouracil metabolism 378

Vanadate, inhibition of endoplasmic reticulum Ca^{2+} pump 213
Vascular actions of endothelins 78–88
Vasculature, lung, morphology and morphometry 331
Vasoactive intestinal contractor 74
Vasoconstriction, endothelins 78
Vimentin, effect of calmodulin on expression of 263
Viral infections, catalytic RNAs in therapy 245–254

Warfarin, ranitidine interaction 237

Zeitgebers 47, 56
Zollinger Ellison syndrome, ranitidine 235